Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329706 · ClinicalTrials.gov registry record · NA
Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 710
- Enrollment target
NCT00329706: Completed NA study, sponsored by University of California, Los Angeles.
NCT00329706 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 710 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00329706, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 710 participants
- Enrollment target
Study Summary
A brain PET scan is recognized as "reasonable and necessary" for some patients with "a recently established diagnosis of dementia" (Centers for Medicare and Medicaid Services, Decision Memo CAG-00088R, 2004), but evidence is less clear for patients having less severe cognitive problems. A substantial portion of such patients will develop Alzheimer's disease and other forms of dementia, which affect millions of people in the U.S., costing us over $100 billion annually. This project employs a prospective randomized protocol to determine whether PET scanning can help distinguish those patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than is done with current clinical practices alone, and lead to earlier, more effective therapies which extend patients' abilities to think and function independently.
Interventions
- PROCEDURE FDG-PET brain scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2006-06 |
| Est. Completion | 2017-01 |
| Phase | NA |
What the finished NCT00329706 record still lists
NCT00329706 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 1 intervention - of which FDG-PET brain scan is the first listed.
NCT00329706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00329706 about?
NCT00329706 is a clinical study titled "Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)". A brain PET scan is recognized as "reasonable and necessary" for some patients with "a recently established diagnosis of dementia" (Centers for Medicare and Medicaid Services, Decision Memo CAG-00088R, 2004), but evidence is less clear for patients having less severe cognitive problems. A substantia...
What is the current status of trial NCT00329706?
This trial is currently completed. It is a NA study. The enrollment target is 710 participants. The study started on 2006-06. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00329706?
The interventions under investigation include: FDG-PET brain scan (PROCEDURE).
Who is sponsoring clinical trial NCT00329706?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00329706's enrollment target sits among peer trials
710 147th of 2000 higher than 1,853 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia